The surge in coronavirus cases is helping speed up the development of vaccines.
There is a slender silver lining to the out-of-control pandemic: It is hastening the testing of vaccines that could eventually end it.
The surging number of virus cases has already allowed Pfizer and Moderna to accelerate the testing of their vaccines, which appear to be very effective at preventing Covid-19, and it is likely to speed the evaluations of promising vaccine candidates from other pharmaceutical companies, The New York Times’s Rebecca Robbins reports.
Here’s how the trials work:
Late-stage vaccine trials are designed so that the faster participants get sick, the faster drug developers gain enough data to know whether their vaccines are effective.
The trial ends after a certain number of cases — around 150 to 170 — have accrued. That number is chosen to make sure the results have sufficient statistical power to tell how well the vaccine works.
For example, Moderna, which announced on Monday that an early analysis found its vaccine to be 94.5 percent effective, had planned for an outside panel to take a first look at its data after only 53 cases of Covid-19 turned up in its trial. But the nationwide surge in infections helped Moderna blow past that number: The results were based on 95 sick participants.
Hoping to fast-track their testing, drug makers have been setting up trials in virus hot spots all over the world — not just in the United States. For example, Chinese vaccine makers are running late-stage trials of their candidates in countries like the United Arab Emirates, Morocco, Argentina and Peru.
Source: Read Full Article